PMID- 34564939
OWN - NLM
STAT- MEDLINE
DCOM- 20220317
LR  - 20220317
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 10
IP  - 21
DP  - 2021 Nov
TI  - Efficacy and safety of anlotinib in patients with unresectable or metastatic bone 
      sarcoma: A retrospective multiple institution study.
PG  - 7593-7600
LID - 10.1002/cam4.4286 [doi]
AB  - BACKGROUND: Tyrosine kinase inhibitors (TKIs) such as cabozantinib, regorafenib 
      have demonstrated encouraging activity in prolonging progression-free survival 
      (PFS) in several bone sarcoma entities in prospective clinical trials. This 
      retrospective study aims to analyze the safety and efficacy of anlotinib, a novel 
      multi-target TKI, in patients with locally unresectable or metastatic bone 
      sarcoma at three institutions. METHODS: Patients with advanced bone sarcoma 
      administered anlotinib 12 mg once daily, 2 weeks on/1 week off, from June 2018 to 
      June 2020, until disease progression or intolerance of treatment. The primary 
      endpoints were objective response rate (ORR) and PFS. RESULTS: Forty-eight 
      patients were analyzed: 27 have osteosarcoma, 9 have chondrosarcoma, 8 have 
      Ewing's sarcoma, and 3 have chordoma. The median age was 24 years (range, 
      16-68 years), and the median number of prior regimens was 1 (range, 0-4). Until 
      the final follow-up, five patients obtained a partial response and while 24 
      achieved stable disease. The ORR in all patients was 10.4%, and the median PFS 
      was 4.6 months, with a progression-free rate (PFR) at 3 months and 6 months of 
      72.9% and 35.4%, respectively. The ORR and median PFS varied much among tumor 
      subtypes. The most frequent grade 3-4 adverse events (AEs) were pneumothorax, 
      hand-foot syndrome, cholesterol elevation, hypertriglyceridemia, and fatigue. No 
      patients died from anlotinib-related AEs during the study period. CONCLUSIONS: 
      Anlotinib may show promising antitumor activity in unresectable or metastatic 
      bone sarcoma. The ORR and median PFS of anlotnib are similar to those of other 
      targeted drugs in different subtypes of sarcomas. The AEs were generally mild and 
      tolerated well. Further studies of anlotinib in selected subtypes of bone sarcoma 
      are needed.
CI  - (c) 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Liu, Zhiyong
AU  - Liu Z
AUID- ORCID: 0000-0003-2123-7923
AD  - Department of Orthopedics, The Affiliated Cancer Hospital of Zhengzhou University 
      and Henan Cancer Hospital, Zhengzhou, Henan, China.
FAU - Gao, Songtao
AU  - Gao S
AD  - Department of Orthopedics, Henan Provincial People's Hospital and People's 
      Hospital of Zhengzhou University, Zhengzhou, Henan, China.
FAU - Zhu, Liangyu
AU  - Zhu L
AD  - Department of Orthopedics, Zhengzhou Orthopedics Hospital, Zhengzhou, Henan, 
      China.
FAU - Wang, Jiaqiang
AU  - Wang J
AD  - Department of Orthopedics, The Affiliated Cancer Hospital of Zhengzhou University 
      and Henan Cancer Hospital, Zhengzhou, Henan, China.
FAU - Zhang, Peng
AU  - Zhang P
AD  - Department of Orthopedics, The Affiliated Cancer Hospital of Zhengzhou University 
      and Henan Cancer Hospital, Zhengzhou, Henan, China.
FAU - Li, Po
AU  - Li P
AD  - Department of Orthopedics, The Affiliated Cancer Hospital of Zhengzhou University 
      and Henan Cancer Hospital, Zhengzhou, Henan, China.
FAU - Zhang, Fan
AU  - Zhang F
AD  - Department of Orthopedics, The Affiliated Cancer Hospital of Zhengzhou University 
      and Henan Cancer Hospital, Zhengzhou, Henan, China.
FAU - Yao, Weitao
AU  - Yao W
AD  - Department of Orthopedics, The Affiliated Cancer Hospital of Zhengzhou University 
      and Henan Cancer Hospital, Zhengzhou, Henan, China.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20210926
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Indoles)
RN  - 0 (Quinolines)
RN  - 0 (anlotinib)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/*adverse effects/*therapeutic use
MH  - Bone Neoplasms/*drug therapy/pathology
MH  - Humans
MH  - Indoles/*adverse effects/*therapeutic use
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Osteosarcoma/*drug therapy/pathology
MH  - Progression-Free Survival
MH  - Protein-Tyrosine Kinases/*antagonists & inhibitors
MH  - Quinolines/*adverse effects/*therapeutic use
MH  - Retrospective Studies
MH  - Young Adult
PMC - PMC8559478
OTO - NOTNLM
OT  - anlotinib
OT  - bone sarcoma
OT  - progression-free survival
OT  - safety
COIS- All authors declare no competing interests.
EDAT- 2021/09/27 06:00
MHDA- 2022/03/18 06:00
PMCR- 2021/09/26
CRDT- 2021/09/26 21:17
PHST- 2021/07/20 00:00 [revised]
PHST- 2021/04/15 00:00 [received]
PHST- 2021/08/20 00:00 [accepted]
PHST- 2021/09/27 06:00 [pubmed]
PHST- 2022/03/18 06:00 [medline]
PHST- 2021/09/26 21:17 [entrez]
PHST- 2021/09/26 00:00 [pmc-release]
AID - CAM44286 [pii]
AID - 10.1002/cam4.4286 [doi]
PST - ppublish
SO  - Cancer Med. 2021 Nov;10(21):7593-7600. doi: 10.1002/cam4.4286. Epub 2021 Sep 26.